イリノイ州における濾胞性リンパ腫の臨床試験
イリノイ州内の拠点で、濾胞性リンパ腫に関する14件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- 他18件
被験者募集中第3相
12歳以上 · 全性別 · 2026/10/02更新 · NCT07215910A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- The University of Chicago Medical Center (UCMC), Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Northwestern Memorial Hospital, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT05765812A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Evanston
- Research Site, Peoria
被験者募集中第3相
18歳〜130歳 · 全性別 · 2026/09/21更新 · NCT06549595Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06526793Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Chicago, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
- Ruth M. Rothstein CORE Center, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06651177A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Northwestern University, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Local Institution - 0240, Arlington Heights
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/20更新 · NCT06911502The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Illinois at Chicago Cancer Center, Chicago
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- The University of Chicago Medical Center, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/20更新 · NCT04830137AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Northwestern Memorial Hospital, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2025/12/10更新 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。